MENARINI Group
Edit

MENARINI Group

http://www.menarini.com/
Last activity: 30.07.2025
Active
Categories: Content DistributionDiagnosticsDrugHealthTechManufacturingMedtechProductProductionResearchService
The Menarini Group is the leading Italian pharmaceutical company in the world, a guarantee of internationally recognised quality. The achieved results are proof of an efficient strategy based on Research, Innovation and Internationalisation, along with the ability to recognize and meet the needs of physicians and patients alike.

One of the Menarini Group's strong points is its collaboration with international partners: the goal is to create synergies that give rise to cutting-edge solutions, pharmaceutical products, and services in the health sector.

At Menarini, quality is the basis of a shared Group strategy. All company structures are involved at different levels in the drug manufacturing process: an efficient system that has created a unique work standard for ensuring quality in every phase, from research to production, from distribution to providing scientific information. All for achieving a common goal: excellence.

With a consolidated turnover in 2020 of 3,750 billion euro, Menarini Group is present in 140 countries with 17.650 employees .
With 10 R&D centers and 18 manufacturing sites, in 2020 Menarini produced 581 million packs of product.
Website visits
36.5K /mo.
Mentions
60
Location: Italy, Tuscany, Florence
Employees: 10001+
Founded date: 1886

Mentions in press and media 60

DateTitleDescription
30.07.2025NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CE...
05.07.2025FAIR PLAY MENARINI INTERNATIONAL AWARD, A WAVE OF EMOTIONS MARKS THE 29TH EDITIONFIESOLE, Italy, July 5, 2025 /PRNewswire/ -- A night suspended between history and legend, dedicated to the most authentic values of ethics and fair play. In the timeless setting of the Roman Theatre of Fiesole, where culture met sport, the...
02.07.2025FAIR PLAY MENARINI INTERNATIONAL AWARD: THE 29TH EDITION OFFICIALLY BEGINSFLORENCE, Italy, July 2, 2025 /PRNewswire/ -- Medals and records alone are not enough to make history and actions, choices, and the way one conducts oneself, can speak louder than any achievement. With this spirit, the 29th edition of the F...
29.05.2025New Frontiers in Cancer Treatment: Elacestrant and Kidney Cancer MonitoringIn the relentless battle against cancer, innovation is the sword and shield. Two recent developments shine a light on this ongoing fight: the promising data surrounding elacestrant for breast cancer and the completion of a significant kidne...
23.05.2025Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual MeetingPreliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented....
15.05.2025DeepL's HIPAA Compliance: A New Era for Healthcare CommunicationIn a world where communication is key, DeepL has taken a giant leap. The company recently announced its compliance with the Health Insurance Portability and Accountability Act (HIPAA). This is not just a box checked; it’s a commitment to se...
14.05.2025Campaign Asia-Pacific Supercharges Campaign360 2025 with Expanded Theatre Stages!HONG KONG, May 14, 2025 /PRNewswire/ -- Get ready for Campaign360 2025 on May 27-28 at the iconic Marina Bay Sands in Singapore! This year, Campaign Asia-Pacific, owned by Haymarket Media Limited, is elevating brand marketing with expanded ...
20.03.2025Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enha...
15.03.2025Insilico Medicine: $110 Million (Series E) Raised For Advancing AI-Based Drug DiscoveryInsilico Medicine (see Pulse 2.0 profile here), a clinical-stage generative AI-driven drug discovery company, announced that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group ...
13.03.2025Insilico Medicine Raises $110M in Series E FinancingInsilico Medicine, a Cambridge, MA-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, raised $110M in Series E funding. The round was led by Value Partners Group (HKG:0806) with participation from ne...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In